Payment overview · 2025
General Payments
$270.63
12 reported records · 7 companies
Healthcare provider profile · identity verified
Ninad P Shet, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROSWELL, NM · NPI 1346521218
Verified facts
What the public records show
CMS Open Payments records show Ninad P Shet, MD received $270.63 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.09 | 50.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.35 | 12.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.84 | 9.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.78 | 8.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.95 | 7.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.35 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.27 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.36 | 11 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.19 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.90 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 71 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 759 | 253 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 134 |
| Lisinopril | Lisinopril | 378 | 123 |
| Metformin Hcl | Metformin Hcl | 362 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 99 |
| Losartan Potassium | Losartan Potassium | 343 | 109 |
| Gabapentin | Gabapentin | 244 | 88 |
| Jardiance | Empagliflozin | 207 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 192 | 59 |
| Omeprazole | Omeprazole | 189 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 70 |
| Glipizide | Glipizide | 187 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 64 |
| Ozempic | Semaglutide | 156 | 40 |
| Naproxen | Naproxen | 151 | 43 |
| Sertraline Hcl | Sertraline Hcl | 138 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 53 |
| Farxiga | Dapagliflozin Propanediol | 126 | 40 |
| Famotidine | Famotidine | 122 | 48 |
| Trazodone Hcl | Trazodone Hcl | 115 | 41 |
| Trulicity | Dulaglutide | 115 | 36 |
| Alendronate Sodium | Alendronate Sodium | 114 | 44 |
| Furosemide | Furosemide | 107 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 38 |
| Carvedilol | Carvedilol | 99 | 36 |
| Simvastatin | Simvastatin | 96 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 86 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 24 |
| Tramadol Hcl | Tramadol Hcl | 83 | 23 |
| Montelukast Sodium | Montelukast Sodium | 81 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 31 |
| Potassium Chloride | Potassium Chloride | 78 | 26 |
| Celecoxib | Celecoxib | 74 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 27 |
| Finasteride | Finasteride | 72 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 18 |
| Januvia | Sitagliptin Phosphate | 66 | 23 |
| Pregabalin | Pregabalin | 64 | 16 |
| Buspirone Hcl | Buspirone Hcl | 62 | 23 |
| Rybelsus | Semaglutide | 62 | 17 |
| Ibuprofen | Ibuprofen | 59 | 24 |
| Glipizide Er | Glipizide | 58 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Prednisone | Prednisone | 49 | 25 |
| Donepezil Hcl | Donepezil Hcl | 46 | 20 |
| Lovastatin | Lovastatin | 46 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 14 |
| Spironolactone | Spironolactone | 44 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 15 |
| Memantine Hcl | Memantine Hcl | 38 | 16 |
| Baclofen | Baclofen | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 36 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 28 |
| Atenolol | Atenolol | 29 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Azithromycin | Azithromycin | 27 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 12 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Kevzara | Sarilumab | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Ibu | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $270.63 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, JARDIANCE, MAVYRET, Ozempic, VRAYLAR, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error